1. South Africa Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Aspen Pharmacare Holdings Limited

Aspen Pharmacare Holdings Limited

APNHY
Aspen Pharmacare Holdings LimitedUS flagOther OTC
9.03
USD
-0.38
- -
4.01BMarket Cap
Aspen Pharmacare Holdings Limited
APNHY
(Other OTC)

Recent

price

9.03

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
23.93
28.6
34.97
42.4
64.71
79.11
78
90.3
83.95
77.81
73.73
82.73
85.22
91.65
100.64
97.66
Revenue per Share
4.92
5.95
6.46
7.73
10.98
11.4
9.42
11.24
13.23
14.16
10.22
10.53
14.32
11.77
9.91
-2.44
Basic EPS, GAAP
1.84
3.71
0.66
-0.74
3.59
5.26
0.88
10.93
-2.65
5.3
18.09
14.95
11.86
12.43
14.01
11.62
Free Cash Flow per Basic Share
- -
0.7
1.05
1.57
1.57
1.97
2.19
2.7
2.88
3.15
- -
- -
2.64
3.28
3.43
3.61
Dividend per Share
26.92
30.35
10.78
8.76
50.51
60.49
66.83
73.47
84.17
94.95
105.15
115.76
124.41
135.41
141.33
135.38
Book Value per Share
4.13
-0.97
0.42
-4.63
-29.52
-24.98
-27.61
-51.61
-63.35
-37.04
-20.15
13.42
27.12
39.48
29.58
28.11
Tangible Book Value per Share
402
433
436
455
456
456
456
456
456
456
456
456
453
444
444
444
Basic Weighted Avg Shares
9,619
12,383
15,256
19,308
29,515
36,100
35,600
41,213
38,314
35,514
33,659
37,766
38,606
40,709
44,706
43,363
Sales/Revenue/Turnover
26.24
25.43
25.83
26.12
25.16
23.27
28.65
23.66
25.74
24.3
24.08
21.51
22.77
20.26
23.37
19.89
Operating Margin (%)
270
359
- -
- -
824
1,000
1,200
1,267
1,372
1,274
1,603
1,653
1,713
1,788
1,973
2,089
Depreciation Expense
1,978
2,578
2,818
3,520
5,008
5,200
4,300
5,128
6,037
6,463
4,664
4,806
6,488
5,228
4,404
-1,083
Net Income, GAAP
21.25
21.27
22.45
21.72
21.25
20
29.51
17.98
16.64
28.54
19.49
19.89
20.24
20.24
22.93
- -
Effective Tax Rate (%)
20.57
20.82
18.47
18.23
16.97
14.4
12.08
12.44
15.76
18.2
13.86
12.73
16.81
12.84
9.85
-2.5
Profit Margin (%)
1,793
1,166
3,112
2,912
15,171
10,900
16,100
2,557
11,293
16,113
18,659
-4,046
11,166
21,352
19,784
21,206
Working Capital
2,647
4,249
6,254
8,924
29,916
25,500
32,700
28,978
46,725
39,713
36,019
266
10,582
21,375
25,141
31,508
LT Debt
10,886
13,287
17,398
22,799
28,876
34,100
42,500
42,391
49,375
54,213
69,217
65,627
70,942
86,236
84,861
84,893
Total Equity
14.14
12.37
12.08
11.67
10.91
9.59
8.99
8.97
8.23
5.82
6.05
6.37
7.52
6.22
6.74
- -
Return on Invested Capital (%)
16.99
15.18
17.93
23.15
14.94
10.68
8.13
8.87
8.82
8.58
6.6
6.87
9.08
7.48
6.49
- -
Return on Capital (%)
26.45
21.52
31.58
80.99
37.06
20.54
14.8
16.02
16.78
15.81
10.21
9.53
11.88
8.97
7.16
-1.76
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.12%
4.58%
0.04%
Free Cash Flow
84.06%
-8.05%
-17.12%
Net Income, GAAP
-12.28%
-24.35%
-124.59%
Sales/Revenue/Turnover
2.15%
5.34%
-3%
Total Cash Common Dividend
- -
- -
4.98%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
44,706
2025
- -
- -
- -
- -
43,363
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
9.91
2025
- -
- -
- -
- -
-2.44
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
3.43
2025
- -
- -
- -
- -
3.61
2026
- -
- -
- -
- -
- -
Similar Companies
iX Biopharma Ltd. (42C.SI)
Johnson Chemical Pharmaceutical Works Co., Ltd. (4747.TWO)
Cipher Pharmaceuticals Inc. (CPH.TO)
DrazCanna, Inc. (DZCA)
China Resources Jiangzhong Pharmaceutical Co.,Ltd (600750.SS)
ApicHope Pharmaceutical Co., Ltd (300723.SZ)
Business
Aspen Pharmacare Holdings Limited, operating through its global subsidiaries, develops, manufactures, and distributes a comprehensive portfolio of specialty and branded pharmaceutical products internationally. The company functions across its Commercial Pharmaceuticals and Manufacturing divisions. It provides a range of sterile injectable medicines, including general anaesthetics, muscle relaxants, and a significant suite of injectable anticoagulants with a focus on low molecular weight heparins. Additionally, Aspen offers a diverse array of branded consumer, prescription, and over-the-counter health products. These include well-known regional brands addressing various therapeutic areas such as sleeping aids, respiratory conditions, iron supplementation, analgesia, and hormone replacement therapy. Beyond its own branded offerings, the company possesses extensive manufacturing capabilities for active pharmaceutical ingredients (APIs) and finished dose form (FDF) products, which it supplies to third-party customers. Aspen has a rich heritage dating back to 1850, though it was publicly listed in 1997, and maintains its headquarters in uMhlanga, South Africa. Recent strategic initiatives include the acquisition of Sandoz's Chinese operations in late 2023, a significant move into insulin vial production in South Africa, and an expansion into the rapidly evolving weight loss drug market, notably with GLP-1 branded products like Mounjaro.

Company News

APIChatGPT

  • seekingalpha.com

    Aspen Pharmacare Holdings Limited (APNHY) Shareholder/Analyst Call Prepared Remarks Transcript

  • seekingalpha.com

    Aspen Pharmacare Holdings Limited (APNHY) Q2 2026 Earnings Call Transcript

  • reuters.com

    Aspen Pharmacare aims for Canada entry with Ozempic generic by third quarter

  • seekingalpha.com

    Aspen Pharmacare Holdings Limited (APNHY) Discusses Proposed Divestment of APAC Operations Excluding China Transcript

  • seekingalpha.com

    Aspen Pharmacare Holdings Limited (APNHY) Q4 2025 Earnings Call Transcript

  • seekingalpha.com

    Aspen Pharmacare Holdings Limited (APNHF) Q2 2025 Earnings Call Transcript

  • seekingalpha.com

    Aspen Pharmacare Holdings Limited (APNHF) Q4 2024 Earnings Call Transcript

  • seekingalpha.com

    Aspen Pharmacare Holdings Limited (APNHF) Q4 2023 Earnings Call Transcript

  • seekingalpha.com

    Aspen Pharmacare Holdings Limited (APNHF) Q4 2022 Earnings Call Transcript

  • zacks.com

    New Strong Sell Stocks for July 11th

  • zacks.com

    New Strong Sell Stocks for March 22nd

  • seekingalpha.com

    Aspen Pharmacare Holdings Limited (APNHF) CEO Stephen Saad on Interim 2022 Results - Earnings Call Transcript

  • zacks.com

    New Strong Sell Stocks for February 28th

  • zacks.com

    ASPEN PHARMACR (APNHY) is on the Move, Here's Why the Trend Could be Sustainable

  • seekingalpha.com

    Aspen Pharmacare Holdings Limited (APNHF) CEO Stephen Saad on Q4 2021 Results - Earnings Call Transcript

  • zacks.com

    Here's Why "Trend" Investors Would Love Betting on ASPEN PHARMACR (APNHY)

  • zacks.com

    What Makes ASPEN PHARMACR (APNHY) a Good Fit for "Trend Investing"

  • seekingalpha.com

    Aspen Pharmacare Holdings Limited (APNHF) CEO Stephen Saad Presents H1 2021 Results at JP Morgan Healthcare Conference (Transcript)

  • thelincolnianonline.com

    ASPEN PHARMACAR/ADR (OTCMKTS:APNHY) Downgraded by Zacks Investment Research